Association Between Sex and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta Analysis

References

• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 359(6382), 7–8 (2018).
   Web of Science ®Google Scholar
• Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat. Rev. Clin. Oncol. 19(1), 7–8 (2022).
   PubMed Web of Science ®Google Scholar
• Zhao B, Zhao H, Zhao J. Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials. Ther. Adv. Med. Oncol. 12, 1758835920937612 (2020).
   Web of Science ®Google Scholar
• Haupt S, Caramia F, Klein SL, Rubin JB, Haupt Y. Sex disparities matter in cancer development and therapy. Nat. Rev. Cancer 21(6), 7–8 (2021).
   Web of Science ®Google Scholar
• Ye Y, Jing Y, Li L et al. Sex-associated molecular differences for cancer immunotherapy. Nat Commun. 11(1), 1779 (2020).
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis. Lancet Oncol. 19(6), 7–8 (2018).
   PubMed Web of Science ®Google Scholar
• Wallis C, Butaney M, Satkunasivam R et al. Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 5(4), 7–8 (2019).
   Web of Science ®Google Scholar
• Yang F, Markovic SN, Molina JR et al. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 3(8), e2012534 (2020).
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J. Natl Cancer Inst. 111(8), 7–8 (2019).
   PubMedGoogle Scholar
• Liang J, Hong J, Tang X et al. Sex difference in response to non-small-cell lung cancer immunotherapy: an updated meta-analysis. Ann. Med. 54(1), 7–8 (2022).
   Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary. Control. Clin. Trials 17(1), 7–8 (1996).
   Google Scholar
• Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach. BMJ (Clinical research ed.). 356, j573 (2017).
   PubMedGoogle Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 327(7414), 7–8 (2003).
   PubMedGoogle Scholar
• Kelley RK, Ueno M, Yoo C et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 401(10391), 7–8 (2023).
   Web of Science ®Google Scholar
• Diaz LA Jr , Shiu KK, Kim TW et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, Phase III study. Lancet Oncol. 23(5), 7–8 (2022).
   Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st randomized clinical trial. JAMA 326(10), 7–8 (2021).
   Web of Science ®Google Scholar
• Doki Y, Ajani JA, Kato K et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386(5), 7–8 (2022).
   PubMed Web of Science ®Google Scholar
• Lu Z, Wang J, Shu Y et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, Phase III trial. BMJ 377, e068714 (2022).
   PubMedGoogle Scholar
• Wang ZX, Cui C, Yao J et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center Phase III trial. Cancer Cell 40(3), 277–288.e3 (2022).
   PubMed Web of Science ®Google Scholar
• Song Y, Zhang B, Xin D et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind Phase III trial. Nat. Med. 29(2), 7–8 (2023).
   Web of Science ®Google Scholar
• Xu J, Kato K, Raymond E et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, Phase III study. Lancet Oncol. 24(5), 7–8 (2023).
   Web of Science ®Google Scholar
• Sun JM, Shen L, Shah MA et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, Phase III study. Lancet 398(10302), 7–8 (2021).
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 Phase III Randomized Clinical Trial. JAMA Oncol. 6(10), 7–8 (2020).
   Web of Science ®Google Scholar
• Moehler M, Dvorkin M, Boku N et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J. Clin. Oncol. 39(9), 966–977 (2021).
   PubMed Web of Science ®Google Scholar
• Kang YK, Chen LT, Ryu MH et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 23(2), 7–8 (2022).
   Web of Science ®Google Scholar
• Shitara K, Ajani JA, Moehler M et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603(7903), 7–8 (2022).
   PubMed Web of Science ®Google Scholar
• Lim M, Weller M, Idbaih A et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-oncology 24(11), 7–8 (2022).
   Web of Science ®Google Scholar
• Omuro A, Brandes AA, Carpentier AF et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized Phase III trial. Neuro-oncology 25(1), 7–8 (2023).
   Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J. Hepatol. 76(4), 7–8 (2022).
   Web of Science ®Google Scholar
• Qin S, Chan SL, Gu S et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international Phase III study. Lancet 402(10408), 1133–1146 (2023).
   PubMed Web of Science ®Google Scholar
• Burtness B, Harrington KJ, Greil R et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase III study. Lancet 394(10212), 7–8 (2019).
   Web of Science ®Google Scholar
• Haddad RI, Harrington K, Tahara M et al. Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. J. Clin. Oncol. 41(12), 2166–2180 (2023).
   PubMed Web of Science ®Google Scholar
• Psyrri A, Fayette J, Harrington K et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, Phase III study. Ann. Oncol. 34(3), 7–8 (2023).
   PubMed Web of Science ®Google Scholar
• Peters S, Scherpereel A, Cornelissen R et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 33(5), 7–8 (2022).
   Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 7–8 (2011).
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31(5), 616–622 (2013).
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372(4), 7–8 (2015).
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Stroyakovskiy D, Gogas H et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, Phase III study. Lancet Oncol. 24(1), 7–8 (2023).
   Web of Science ®Google Scholar
• Carbone DP, Reck M, Paz-Ares L et al. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N. Engl. J. Med. 376(25), 7–8 (2017).
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG et al. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J. Clin. Oncol. 37(7), 7–8 (2019).
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Cho BC, Reinmuth N et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small-cell lung cancer: the MYSTIC Phase III randomized clinical trial. JAMA Oncol. 6(5), 7–8 (2020).
   Web of Science ®Google Scholar
• Sezer A, Kilickap S, Gümüş M et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, Phase III, randomised, controlled trial. Lancet 397(10274), 7–8 (2021).
   Web of Science ®Google Scholar
• Jassem J, de Marinis F, Giaccone G et al. Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC. J. Thorac. Oncol. 16(11), 7–8 (2021).
   Web of Science ®Google Scholar
• Paz-Ares LG, Ramalingam SS, Ciuleanu TE et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, Phase III CheckMate 227 Part 1 Trial. J. Thorac. Oncol. 17(2), 7–8 (2022).
   Web of Science ®Google Scholar
• Peters S, Dziadziuszko R, Morabito A et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized Phase III trial. Nat. Med. 28(9), 7–8 (2022).
   PubMed Web of Science ®Google Scholar
• Gogishvili M, Melkadze T, Makharadze T et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small-cell lung cancer: a randomized, controlled, double-blind Phase III trial. Nat. Med. 28(11), 7–8 (2022).
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu L, Li B et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized Phase III trial (CHOICE-01). J. Clin. Oncol. 41(3), 7–8 (2023).
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lee JS, Ciuleanu TE et al. Five-year survival outcomes with nivolumab plus ipilimumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer in CheckMate 227. J. Clin. Oncol. 41(6), 7–8 (2023).
   PubMed Web of Science ®Google Scholar
• de Castro G Jr , Rizvi NA, Schmid P et al. NEPTUNE: Phase III study of first-line durvalumab plus tremelimumab in patients with metastatic NSCLC. J. Thorac. Oncol. 18(1), 106–119 (2023).
   PubMed Web of Science ®Google Scholar
• Spigel DR, Faivre-Finn C, Gray JE et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40(12), 1301–1311 (2022).
   PubMed Web of Science ®Google Scholar
• de Castro G Jr , Kudaba I, Wu YL et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥1% in the KEYNOTE-042 study. J. Clin. Oncol. 41(11), 1986–1991 (2023).
   PubMed Web of Science ®Google Scholar
• Johnson ML, Cho BC, Luft A et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the Phase III POSEIDON study. J. Clin. Oncol. 41(6), 1213–1227 (2023).
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang Z, Sun M et al. Interim survival analysis of the randomized Phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC. Nat Cancer. 4(6), 860–871 (2023).
   PubMedGoogle Scholar
• Lee SM, Schulz C, Prabhash K et al. First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a Phase III, global, multicentre, open-label, randomised controlled study. Lancet 402(10400), 451–463 (2023).
   PubMed Web of Science ®Google Scholar
• West H, McCleod M, Hussein M et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, Phase III trial. Lancet Oncol. 20(7), 924–937 (2019).
   PubMed Web of Science ®Google Scholar
• Nishio M, Barlesi F, West H et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized Phase III IMpower132 trial. J. Thorac. Oncol. 16(4), 653–664 (2021).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Abreu D, Powell SF, Hochmair MJ et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann. Oncol. 32(7), 881–895 (2021).
   PubMed Web of Science ®Google Scholar
• Socinski MA, Nishio M, Jotte RM et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. J. Thorac. Oncol. 16(11), 1909–1924 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang Z, Fang J et al. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase III ORIENT-11 study. Lung Cancer. 171, 56–60 (2022).
   PubMed Web of Science ®Google Scholar
• Zhou C, Chen G, Huang Y et al. Camrelizumab plus carboplatin and pemetrexed as first-line treatment for advanced nonsquamous NSCLC: extended follow-up of CameL Phase III trial. J. Thorac. Oncol. 18(5), 628–639 (2023).
   PubMed Web of Science ®Google Scholar
• Govindan R, Szczesna A, Ahn MJ et al. Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J. Clin. Oncol. 35(30), 3449–3457 (2017).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379(21), 2040–2051 (2018).
   PubMed Web of Science ®Google Scholar
• Jotte R, Cappuzzo F, Vynnychenko I et al. Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial. J. Thorac. Oncol. 15(8), 1351–1360 (2020).
   PubMed Web of Science ®Google Scholar
• Ren S, Chen J, Xu X et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a Phase III trial. J. Thorac. Oncol. 17(4), 544–557 (2022).
   PubMed Web of Science ®Google Scholar
• Reck M, Luft A, Szczesna A et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J. Clin. Oncol. 34(31), 3740–3748 (2016).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, Phase III KEYNOTE-604 study. J. Clin. Oncol. 38(21), 2369–2379 (2020).
   PubMed Web of Science ®Google Scholar
• Liu SV, Reck M, Mansfield AS et al. Updated overall survival and pd-l1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39(6), 619–630 (2021).
   PubMed Web of Science ®Google Scholar
• Owonikoko TK, Park K, Govindan R et al. Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: checkMate 451. J. Clin. Oncol. 39(12), 1349–1359 (2021).
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Chen Y, Reinmuth N et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 7(2), 100408 (2022).
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou C, Yao W et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 23(6), 739–747 (2022).
   PubMed Web of Science ®Google Scholar
• Cheng Y, Han L, Wu L et al. Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA 328(12), 1223–1232 (2022).
   PubMed Web of Science ®Google Scholar
• Galsky MD, Arija JÁA, Bamias A et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled Phase III trial. Lancet 395(10236), 1547–1557 (2020).
   PubMed Web of Science ®Google Scholar
• Powles T, van der Heijden MS, Castellano D et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, Phase III trial. Lancet Oncol. 21(12), 1574–1588 (2020).
   PubMed Web of Science ®Google Scholar
• Powles T, Csőszi T, Özgüroğlu M et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, Phase III trial. Lancet Oncol. 22(7), 931–945 (2021).
   PubMed Web of Science ®Google Scholar
• Grivas P, Park SH, Voog E et al. Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 Phase III trial. Eur. Urol. 84(1), 95–108 (2023).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Rini BI et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann. Oncol. 31(8), 1030–1039 (2020).
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N. Engl. J. Med. 384(14), 1289–1300 (2021).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, McDermott DF, Escudier B et al. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128(11), 2085–2097 (2022).
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384(9), 829–841 (2021).
   PubMed Web of Science ®Google Scholar
• Plimack ER, Powles T, Stus V et al. Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the Phase III KEYNOTE-426 study. Eur. Urol. 84(5), 449–454 (2023).
   PubMed Web of Science ®Google Scholar
• Kojima T, Shah MA, Muro K et al. Randomized Phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J. Clin. Oncol. 38(35), 4138–4148 (2020).
   PubMed Web of Science ®Google Scholar
• Kato K, Cho BC, Takahashi M et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, Phase III trial. Lancet Oncol. 20(11), 1506–1517 (2019).
   PubMed Web of Science ®Google Scholar
• Huang J, Xu J, Chen Y et al. Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, Phase III study. Lancet Oncol. 21(6), 832–842 (2020).
   PubMed Web of Science ®Google Scholar
• Shen L, Kato K, Kim SB et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized Phase III study. J. Clin. Oncol. 40(26), 3065–3076 (2022).
   PubMed Web of Science ®Google Scholar
• Bang YJ, Ruiz EY, Van Cutsem E et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann. Oncol. 29(10), 2052–2060 (2018).
   PubMed Web of Science ®Google Scholar
• Chen LT, Satoh T, Ryu MH et al. A Phase III study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 23(3), 510–519 (2020).
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Özgüroğlu M, Bang YJ et al. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized Phase III KEYNOTE-061 trial. Gastric Cancer. 25(1), 197–206 (2022).
   PubMed Web of Science ®Google Scholar
• Finn RS, Ryoo BY, Merle P et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J. Clin. Oncol. 38(3), 193–202 (2020).
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr , Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375(19), 1856–1867 (2016).
   PubMed Web of Science ®Google Scholar
• Cohen E, Soulières D, Le Tourneau C et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, Phase III study. Lancet 393(10167), 156–167 (2019).
   PubMed Web of Science ®Google Scholar
• Ferris RL, Haddad R, Even C et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label Phase III study. Ann. Oncol. 31(7), 942–950 (2020).
   PubMed Web of Science ®Google Scholar
• Popat S, Curioni-Fontecedro A, Dafni U et al. A multicentre randomised Phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9–15) PROMISE-meso trial. Ann. Oncol. 31(12), 1734–1745 (2020).
   PubMed Web of Science ®Google Scholar
• Fennell DA, Ewings S, Ottensmeier C et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, Phase III trial. Lancet Oncol. 22(11), 1530–1540 (2021).
   PubMed Web of Science ®Google Scholar
• Larkin J, Minor D, D’Angelo S et al. Overall Survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label Phase III trial. J. Clin. Oncol. 36(4), 383–390 (2018).
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, von Pawel J, Park K et al. Updated efficacy analysis including secondary population results for OAK: a randomized Phase III study of atezolizumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer. J. Thorac. Oncol. 13(8), 1156–1170 (2018).
   PubMed Web of Science ®Google Scholar
• Planchard D, Reinmuth N, Orlov S et al. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann. Oncol. 31(5), 609–618 (2020).
   PubMed Web of Science ®Google Scholar
• Lu S, Wang J, Cheng Y et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small-cell lung cancer: 2-year follow-up from a randomized, open-label, Phase III study (CheckMate 078). Lung Cancer. 152, 7–14 (2021).
   PubMed Web of Science ®Google Scholar
• Herbst RS, Garon EB, Kim DW et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J. Thorac. Oncol. 16(10), 1718–1732 (2021).
   PubMed Web of Science ®Google Scholar
• Park K, Özgüroğlu M, Vansteenkiste J et al. Avelumab versus docetaxel in patients with platinum-treated advanced NSCLC: 2-year follow-up from the JAVELIN Lung 200 Phase III trial. J. Thorac. Oncol. 16(8), 1369–1378 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou C, Huang D, Fan Y et al. Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a Phase III, open-label, randomized controlled trial. J. Thorac. Oncol. 18(1), 93–105 (2023).
   PubMed Web of Science ®Google Scholar
• Ren S, Feng J, Ma S et al. KEYNOTE-033: randomized Phase III study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC. Int. J. Cancer 153(3), 623–634 (2023).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373(17), 1627–1639 (2015).
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373(2), 123–135 (2015).
   PubMed Web of Science ®Google Scholar
• Shi Y, Wu L, Yu X et al. Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled Phase III trial (ORIENT-3). Cancer Commun. 42(12), 1314–1330 (2022).
   Web of Science ®Google Scholar
• Spigel DR, Vicente D, Ciuleanu TE et al. Second-line nivolumab in relapsed small-cell lung cancer: checkMate 331(*). Ann. Oncol. 32(5), 631–641 (2021).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, de Wit R, Vaughn DJ et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376(11), 1015–1026 (2017).
   PubMed Web of Science ®Google Scholar
• Pal SK, Albiges L, Tomczak P et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, Phase III trial. Lancet 402(10397), 185–195 (2023).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Ajani JA, Kuzdzal J et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384(13), 1191–1203 (2021).
   PubMed Web of Science ®Google Scholar
• Eggermont A, Chiarion-Sileni V, Grob JJ et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind Phase III randomised trial. Eur. J. Cancer 119, 1–10 (2019).
   PubMed Web of Science ®Google Scholar
• Eggermont A, Blank CU, Mandala M et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III Melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J. Clin. Oncol. 38(33), 3925–3936 (2020).
   PubMed Web of Science ®Google Scholar
• Luke JJ, Rutkowski P, Queirolo P et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, Phase III trial. Lancet 399(10336), 1718–1729 (2022).
   PubMed Web of Science ®Google Scholar
• Felip E, Altorki N, Zhou C et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, Phase III trial. Lancet 398(10308), 1344–1357 (2021).
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N. Engl. J. Med. 386(21), 1973–1985 (2022).
   PubMed Web of Science ®Google Scholar
• O’Brien M, Paz-Ares L, Marreaud S et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, Phase III trial. Lancet Oncol. 23(10), 1274–1286 (2022).
   PubMed Web of Science ®Google Scholar
• Wakelee H, Liberman M, Kato T et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N. Engl. J. Med. 389(6), 491–503 (2023).
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Hussain M, Gschwend JE et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, Phase III trial. Lancet Oncol. 22(4), 525–537 (2021).
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Witjes JA, Gschwend JE et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384(22), 2102–2114 (2021).
   PubMed Web of Science ®Google Scholar
• Powles T, Tomczak P, Park SH et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 23(9), 1133–1144 (2022).
   PubMed Web of Science ®Google Scholar
• Pal SK, Uzzo R, Karam JA et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, Phase III trial. Lancet 400(10358), 1103–1116 (2022).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Russo P, Grünwald V et al. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, Phase III trial. Lancet 401(10379), 821–832 (2023).
   PubMed Web of Science ®Google Scholar
• Castro A, Pyke RM, Zhang X et al. Strength of immune selection in tumors varies with sex and age. Nat Commun. 11(1), 4128 (2020).
   PubMed Web of Science ®Google Scholar
• Yoon HH, Jin Z, Kour O et al. Association of PD-L1 expression and other variables with benefit from immune checkpoint inhibition in advanced gastroesophageal cancer: systematic review and meta-analysis of 17 Phase III randomized clinical trials. JAMA Oncol. 8(10), 1456–1465 (2022).
   PubMed Web of Science ®Google Scholar
• Mo J, Hu X, Gu L et al. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. World J Surg Oncol. 18(1), 15 (2020).
   PubMed Web of Science ®Google Scholar
• Okamoto T, Suzuki Y, Fujishita T et al. The prognostic impact of the amount of tobacco smoking in non-small-cell lung cancer--differences between adenocarcinoma and squamous cell carcinoma. Lung Cancer. 85(2), 125–130 (2014).
   PubMed Web of Science ®Google Scholar
• Xue C, Zheng S, Dong H et al. Association between efficacy of immune checkpoint inhibitors and sex: an updated meta-analysis on 21 Trials and 12,675 non-small-cell lung cancer patients. Front Oncol. 11, 627016 (2021).
   PubMedGoogle Scholar
• Rahman R, Fell G, Ventz S et al. Deviation from the proportional hazards assumption in randomized Phase III clinical trials in oncology: prevalence, associated factors, and implications. Clin. Cancer Res. 25(21), 6339–6345 (2019).
   PubMed Web of Science ®Google Scholar
• Oertelt-Prigione S. The influence of sex and gender on the immune response. Autoimmun Rev. 11(6–7), A479–485 (2012).
   PubMed Web of Science ®Google Scholar
• Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature 509(7500), 282–283 (2014).
   PubMed Web of Science ®Google Scholar
• Button KS, Ioannidis JP, Mokrysz C et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14(5), 365–376 (2013).
   PubMed Web of Science ®Google Scholar
• Hackshaw A. Small studies: strengths and limitations. Eur. Respir. J. 32(5), 1141–1143 (2008).
   PubMed Web of Science ®Google Scholar
• Bilgihan MT, Eryigit AN, Ciftciler R. Efficacy and safety of immune checkpoint inhibitors in hematologic malignancies. Clin. Lymphoma Myeloma Leuk. 24(1), 23–31 (2024).
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, Phase III study. Lancet Oncol. 22(4), 512–524 (2021).
   PubMedGoogle Scholar
• Mateos M-V, Blacklock H, Schjesvold F et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, Phase III trial. Lancet Haematol. 6(9), e459–e469 (2019).
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Schjesvold F, Oriol A et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, Phase III trial. Lancet Haematol. 6(9), e448–e458 (2019).
   PubMed Web of Science ®Google Scholar